Charles N York II's Net Worth
$5.94 Million
Who is Charles N York II?
Charles N York II has an estimated net worth of $5.94 Million. This is based on reported shares across multiple companies, which include Day One Biopharmaceuticals, Inc., and Aeglea BioTherapeutics, Inc..
SEC CIK
Charles N York II's CIK is 0001655962
Past Insider Trading and Trends
2023 was Charles N York II's most active year for acquiring shares with 10 total transactions. Charles N York II's most active month to acquire stocks was the month of December. 2022 was Charles N York II's most active year for disposing of shares, totalling 16 transactions. Charles N York II's most active month to dispose stocks was the month of October. 2017 saw Charles N York II paying a total of $108,248.94 for 172,459 shares, this is the most they've acquired in one year. In 2023 Charles N York II cashed out on 37,640 shares for a total of $470,002.62, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $15.495
COO, CFO AND SECRETARY
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +3.49% | 7.58K |
$16.08 | -$43,010.52 | 224.87K |
May 15 - May 16
| |||
Form 4
| -21.77% | -60.46K |
$17.88 | -$1,081,190.53 | 217.29K |
Scheduled
|
May 1 - May 3
| ||
Form 4
| +2.81% | 7.58K |
$15.25 | -$40,651.43 | 277.75K |
Feb 15 - Feb 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 5
| |||
Form 4
| +1.00% | 2.67K |
$11.69 | -$11,175.64 | 270.17K |
Nov 15 - Nov 16
| |||
Form 4
| +1.02% | 2.7K |
$13.86 | -$12,778.92 | 267.5K |
Aug 15 - Aug 17
| |||
Form 4
| +1.02% | 2.67K |
$13.12 | -$12,531.80 | 264.8K |
May 15 - May 16
| |||
Form 4
| -3.45% | -9.38K |
$20.03 | -$187,790.37 | 262.13K |
Scheduled
|
Feb 17
| ||
Form 4
| +1.00% | 2.69K |
$19.57 | -$18,202.89 | 271.5K |
Feb 15 - Feb 16
| |||
Form 4
| -3.59% | -10.00K |
$22.75 | -$227,523.00 | 268.81K |
Scheduled
|
Jan 20
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 4
| -3.49% | -10.00K |
$20.07 | -$200,650.00 | 276.5K |
Scheduled
|
Dec 20
| ||
Form 4
| -3.37% | -10.00K |
$20.76 | -$207,569.78 | 286.5K |
Scheduled
|
Nov 21
| ||
Form 4
| +0.16% | 945 |
$21.46 | -$9,227.71 | 592.27K |
Nov 15 - Nov 16
| |||
Form 4
| -3.29% | -10.00K |
$20.03 | -$200,313.00 | 294.4K |
Scheduled
|
Nov 1
| ||
Form 4
| -3.18% | -10.00K |
$20.05 | -$200,473.00 | 304.4K |
Scheduled
|
Oct 3
| ||
Form 4
| -3.08% | -10.00K |
$23.25 | -$232,484.32 | 314.4K |
Scheduled
|
Sep 1
| ||
Form 4
| +0.94% | 3.04K |
$24.31 | -$26,473.59 | 324.4K |
Aug 15 - Aug 16
| |||
Form 4
| -3.02% | -10.00K |
$20.05 | -$200,541.00 | 321.37K |
Scheduled
|
Aug 4
| ||
Form 4
| -0.75% | -2.50K |
$20.00 | -$50,000.00 | 331.37K |
Scheduled
|
Jul 18
| ||
Form 4
| -0.42% | -1.42K |
$20.00 | -$28,320.00 | 333.87K |
Scheduled
|
Jul 8
| ||
Form 4
| -0.68% | -2.28K |
$20.00 | -$45,580.00 | 335.28K |
Scheduled
|
Jul 1 - Jul 5
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aeglea BioTherapeutics, Inc. (AGLE) No price found
Chief Financial Officer and VP
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 20
| |||
Form 4
| +294.05% | 25.96K |
$4.48 | $116,222.95 | 34.79K |
Aug 15 - Dec 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
| +171.70% | 12.88K |
—
|
—
| 20.39K |
Apr 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||